Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4088/jcp.v65n0220d | DOI Listing |
Alzheimers Dement
December 2024
King's College London, London, United Kingdom; College of Medicine and Health, University of Exeter, Exeter, United Kingdom.
Psychosis is a common and distressing disorder in people with Alzheimer disease, associated with a poor clinical prognosis, an increased risk of institutionalization and for which there are no approved treatments. New approaches to diagnosis and symptom assessment and treatment are beginning to move the field forward, including the emergence of psychosis at the pre-clinical or even pre-cognitive impairment stages of disease in some individuals. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) research criteria for psychosis in neurodegenerative disease, and the ISTAART criteria for mild behavioural impairment are examples of recent developments.
View Article and Find Full Text PDFBackground: We present Phase 1 trial data using the Neuropsychiatric Inventory ("NPI") domains, NPI-delusions and NPI-hallucinations as symptoms of psychosis in participants with Alzheimer's ("AD") receiving IGC-AD1, a combination of low concentration delta 9-tetrahydrocannabinol ("THC") and melatonin. Cannabis use is considered an established risk factor for psychosis in young people. Psychosis is prevalent in AD patients, with around 50% experiencing it, generating safety concerns regarding the use of THC in these patients.
View Article and Find Full Text PDFBMJ Open
January 2025
Unit for Social and Community Psychiatry, Queen Mary University of London Faculty of Medicine and Dentistry, London, UK.
Background: Approximately 69%-89% of people with severe mental illnesses, particularly psychosis, experience a treatment gap in low- and middle-income countries (LMICs) due to factors such as low public spending on health and weak healthcare systems. The PIECEs project aims to assess the effectiveness and cost-effectiveness of a solution-focused resource-oriented approach (DIALOG+) for improving the quality of life and mental well-being of people with psychosis in India and Pakistan.
Methods: The research design of this analysis is an economic evaluation piggybacked on the PIECEs randomised control trial to test the feasibility of DIALOG+ in India and Pakistan.
Glob Ment Health (Camb)
January 2025
Department of Psychiatry Mbarara University of Science and Technology, Mbarara, Uganda.
Background: Low- and middle-income countries (LMICs) bear a disproportionate burden of mental illness, with limited access to biomedical care. This study examined pathways to care for psychosis in rural Uganda, exploring factors influencing treatment choices.
Methods: We conducted a mixed-methods study in Buyende District, Uganda, involving 67 in-depth interviews and 4 focus group discussions (data collection continued until thematic saturation was reached) with individuals with psychotic disorders, family members, and local leaders.
Transl Psychiatry
January 2025
Department of Neurosciences, Research Group Psychiatry, Center for Contextual Psychiatry, KU Leuven, Leuven, Belgium.
ACT in Daily Life (ACT-DL) is a blended-care Ecological Momentary Intervention that extends ACT into the daily life of individuals, improving psychotic distress, negative symptoms, and global functioning. However, it remains unclear whether ACT-DL works equally for everyone. We investigated whether moderators (i.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!